Replies to post #7088 on GTC Biotherapeutics (fka GTCB)

[mouton29]

"The study you cited had the same eligibility requirements as the Kybersept study, and the predicted probably of death was not used as an entry requirement."

Well, now that I have read some of the ReadmeFirst materials, I am slightly less clueless than before -- I am ashamed I did not understand the point that the Leo trial is limited to patients with DIC.

Obviously there must be some connection between "hypercoagulability" and DIC but I assume you can have hypercoagulability without DIC and I see nothing in the Gonano paper indicating that patients were limited to those with DIC. But I am guessing that hypercoagulability is an aspect of DIC and I would have thought that an improvement in one would be correlated with an improvement in the other.